학술논문

Development of an Experimental Model of Induced Bacterial Peritonitis in Cirrhotic Rats With or Without Ascites.
Document Type
Article
Source
American Journal of Gastroenterology (Springer Nature). Jun2007, Vol. 102 Issue 6, p1230-1236. 7p. 2 Graphs.
Subject
*PERITONITIS
*BACTERIAL diseases
*DISEASE complications
*CIRRHOSIS of the liver
*ESCHERICHIA coli
*LABORATORY rats
*ANIMAL experimentation
Language
ISSN
0002-9270
Abstract
BACKGROUND: Spontaneous bacterial peritonitis (SBP) is a severe complication of cirrhotic patients associated with a high mortality. AIM: To develop an available experimental model of induced bacterial peritonitis in cirrhosis. MATERIAL Sprague-Dawley rats with carbon-tetrachloride-induced cirrhosis with (N = 22) or without (N = 101) AND METHODS: ascites were randomized to receive an intraperitoneal administration of different concentrations of Escherichia coli ( E. coli) diluted in 1 mL of sterile water in ascitic rats and in different volumes in nonascitic rats. A subgroup of nonascitic animals received ceftriaxone 4 h after E. coli inoculation. Mortality of rats was evaluated 24 h after bacterial inoculation. RESULTS: None of the rats receiving sterile water alone and only one infected with 107 cfu of E. coli died. Ascitic rats showed a lower mortality rate than nonascitic rats infected with 108 or 109 cfu of E. coli ( P < 0.05). Mortality was higher with 109 cfu than with 108 cfu of E. coli in ascitic ( P NS) and nonascitic ( P < 0.01) rats. A trend was noted to ward higher mortality in nonascitic rats inoculated with 108 cfu with increasing water volumes. A marked peritoneal polymorphonuclear cell response was observed 4 h after E. coli injection in both ascitic and nonascitic rats. Antibiotic therapy significantly reduced the mortality rate of rats infected with 108 cfu ( P < 0.01). CONCLUSIONS: This experimental model of induced bacterial peritonitis in cirrhosis with or without ascites may represent a useful tool for the study of pathogenic events postinfection and for the design of new therapeutic strategies to treat patients with SBP. [ABSTRACT FROM AUTHOR]